Jia-Wei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jia-Wei Wang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Jinghai Wan
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
5 shared publications Qi Liu
National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College
3 shared publicationsKai-Hua Cao
National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College
2 shared publicationsKe Hu
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing People's Republic of China
2 shared publicationsLiujiazi Shao
Department of Anesthesiology, Beijing Friendship Hospital Capital Medical University Beijing People's Republic of China
2 shared publicationsQing Yuan
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-22
Characterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme
Background: Glioblastoma multiforme (GBM) is a pervasive and aggressive malignant brain tumor. In the tumor immune microenvironment, CD8 + TIM3 + CD101 + T cells (CCT cells) play a pivotal role in tumor progression and immune evasion. This study aimed to characterize differentially expressed genes (DEGs) in CCT cells, establish a prognostic model for GBM, and explore clinical implications. Methods: Analysis of data from TCGA, CGGA, and GEO databases included whole-genome expression profiles, clinical data, single nucleotide mutations, and single-cell RNA sequencing. DEGs were identified, and cell trajectories were constructed using Seurat, Monocle 2, and CellChat packages. Functional enrichment analysis was conducted with clusterProfiler, and a prognostic model was developed. Immune infiltration and drug sensitivity analyses were performed to evaluate therapeutic implications. Results: Eight distinct cell types were distinguished, encompassing T cells, macrophages, neurons, mural cells, endothelial cells, oligodendrocytes, fibroblasts, and B cells. Comparative analysis revealed differences in these cell types between GBM samples with new adjuvant therapy and initial diagnosis controls. Pseudotime analysis indicated CD8 + TIM3 + CD101-T cells as precursors to CCT cells, unveiling unique gene expression patterns during this transition. The prognostic model, incorporating 22 gene features via LASSO regression, demonstrated strong predictive ability through Receiver Operating Characteristic (ROC) curves. Analysis of 28 immune cell types revealed differences between high-risk and low-risk groups, providing insights into GBM’s immune evasion mechanisms. Drug sensitivity analysis proposed potential therapeutic strategies for high-risk patients. Conclusion: This study offers an in-depth understanding of CCT cells in GBM, introducing a novel prognostic model and suggesting promising therapeutic approaches.
- 15 May 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-22
Open AccessCharacterization and prognostic of CD8 + TIM3 + CD101 + T cells in glioblastoma multiforme
Background: Glioblastoma multiforme (GBM) is a pervasive and aggressive malignant brain tumor. In the tumor immune microenvironment, CD8 + TIM3 + CD101 + T cells (CCT cells) play a pivotal role in tumor progression and immune evasion. This study aimed to characterize differentially expressed genes (DEGs) in CCT cells, establish a prognostic model for GBM, and explore clinical implications. Methods: Analysis of data from TCGA, CGGA, and GEO databases included whole-genome expression profiles, clinical data, single nucleotide mutations, and single-cell RNA sequencing. DEGs were identified, and cell trajectories were constructed using Seurat, Monocle 2, and CellChat packages. Functional enrichment analysis was conducted with clusterProfiler, and a prognostic model was developed. Immune infiltration and drug sensitivity analyses were performed to evaluate therapeutic implications. Results: Eight distinct cell types were distinguished, encompassing T cells, macrophages, neurons, mural cells, endothelial cells, oligodendrocytes, fibroblasts, and B cells. Comparative analysis revealed differences in these cell types between GBM samples with new adjuvant therapy and initial diagnosis controls. Pseudotime analysis indicated CD8 + TIM3 + CD101-T cells as precursors to CCT cells, unveiling unique gene expression patterns during this transition. The prognostic model, incorporating 22 gene features via LASSO regression, demonstrated strong predictive ability through Receiver Operating Characteristic (ROC) curves. Analysis of 28 immune cell types revealed differences between high-risk and low-risk groups, providing insights into GBM’s immune evasion mechanisms. Drug sensitivity analysis proposed potential therapeutic strategies for high-risk patients. Conclusion: This study offers an in-depth understanding of CCT cells in GBM, introducing a novel prognostic model and suggesting promising therapeutic approaches.
- Open Access
- 21 June 2023
- Published by Springer Nature in Research Square
Identification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas
Glioma, a prevalent type of brain cancer, is associated with poor prognosis. The purpose of this study was to investigate the correlation between disulfidptosis-related lncRNAs (DRLncs) and survival outcomes of glioma patients. Transcriptome and clinical data for glioma patients were retrieved from The Cancer Genome Atlas (TCGA) database. Ten disulfidptosis-related genes (DRGs) were identified from literature. Co-expression analysis was performed to identify DRLncs associated with glioma. A risk prognostic model for DRLncs was constructed using COX regression analysis and LASSO regression analysis. The model was validated by dividing samples evenly into training and test groups and conducting various analyses including survival analysis, ROC curve analysis, independent prognostic analyses, and PCA. GO and KEGG enrichment analysis was also performed on differentially expressed genes between high-risk and low-risk groups. Variances in the immune microenvironment, immune cells, and immune-related functions were analyzed between high-risk and low-risk groups. Drug sensitivity analysis was conducted to identify potential therapeutic drugs for glioma treatment, and the TIDE database was used to evaluate the potential for immune escape. The expression of DRLncs in glioma was verified through real-time quantitative PCR. Through co-expression analysis, 136 disulfidptosis-related LncRNAs were identified. Univariate Cox analysis revealed that 86 of these LncRNAs significantly correlated with overall survival (OS) in glioma patients. Using the Lasso-Cox method, a model consisting of 7 LncRNAs was constructed and optimized. This model effectively differentiated between individuals at high risk and those at low risk, with good survival prediction ability. GO and KEGG analysis indicated that the differential gene enrichment in the high- and low-risk groups was related to immune-related functions. The study observed divergences in the immune microenvironment, immune cells, and immune-related functions between the high-risk and low-risk groups. Furthermore, immunotherapy response scoring indicated that patients in the low-risk group exhibited better response to immunotherapy. Finally, real-time quantitative PCR results showed that the expression of low-risk LncRNA (ZBTB20-AS4) was low in tumor tissue, while the expression of high-risk LncRNAs (POLR2J4, SUCLG2-AS1, and UBA6-AS1) was high in glioma tumor tissue. Overall, this study established a novel glioma prognosis model that explored disulfidptosis-related lncRNAs to guide glioma prognosis.
- 21 June 2023
- Published by Springer Nature in Research Square
Open AccessIdentification of a Novel Disulfideptosis-Related LncRNA Signature and Integrative Analyses in Patients with Gliomas
Glioma, a prevalent type of brain cancer, is associated with poor prognosis. The purpose of this study was to investigate the correlation between disulfidptosis-related lncRNAs (DRLncs) and survival outcomes of glioma patients. Transcriptome and clinical data for glioma patients were retrieved from The Cancer Genome Atlas (TCGA) database. Ten disulfidptosis-related genes (DRGs) were identified from literature. Co-expression analysis was performed to identify DRLncs associated with glioma. A risk prognostic model for DRLncs was constructed using COX regression analysis and LASSO regression analysis. The model was validated by dividing samples evenly into training and test groups and conducting various analyses including survival analysis, ROC curve analysis, independent prognostic analyses, and PCA. GO and KEGG enrichment analysis was also performed on differentially expressed genes between high-risk and low-risk groups. Variances in the immune microenvironment, immune cells, and immune-related functions were analyzed between high-risk and low-risk groups. Drug sensitivity analysis was conducted to identify potential therapeutic drugs for glioma treatment, and the TIDE database was used to evaluate the potential for immune escape. The expression of DRLncs in glioma was verified through real-time quantitative PCR. Through co-expression analysis, 136 disulfidptosis-related LncRNAs were identified. Univariate Cox analysis revealed that 86 of these LncRNAs significantly correlated with overall survival (OS) in glioma patients. Using the Lasso-Cox method, a model consisting of 7 LncRNAs was constructed and optimized. This model effectively differentiated between individuals at high risk and those at low risk, with good survival prediction ability. GO and KEGG analysis indicated that the differential gene enrichment in the high- and low-risk groups was related to immune-related functions. The study observed divergences in the immune microenvironment, immune cells, and immune-related functions between the high-risk and low-risk groups. Furthermore, immunotherapy response scoring indicated that patients in the low-risk group exhibited better response to immunotherapy. Finally, real-time quantitative PCR results showed that the expression of low-risk LncRNA (ZBTB20-AS4) was low in tumor tissue, while the expression of high-risk LncRNAs (POLR2J4, SUCLG2-AS1, and UBA6-AS1) was high in glioma tumor tissue. Overall, this study established a novel glioma prognosis model that explored disulfidptosis-related lncRNAs to guide glioma prognosis.
- Open Access
- 1 March 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 179-187
Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
Purpose: Several biomarkers, such as baseline neutrophil-to-lymphocyte ratio (NLR), have been more investigated in patients with brain metastases (BM), while their role in patients with leptomeningeal metastases (LM) has not been clarified. Considering the difference between the clinical behaviour of BM and LM, there is the need for addressing the role of these biomarkers in LM. Methods: The present study retrospectively analyzed 95 consecutive patients with LM from lung cancer who were diagnosed at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2016 and December 2019. Baseline NLR, platelet-to-lymphocyte ratio (PLR), systemic immunoinflammation index (SII), and lymphocyte‐to-monocyte ratio at diagnosis of LM were calculated based on complete blood count and correlated, along with other characteristics, with overall survival (OS) using univariate and multivariate analyses. The best cutoff values for systemic immunoinflammation biomarkers were derived using the surv_cutpoint function in R software, which optimized the significance of the split between Kaplan–Meier survival curves. Results: Median OS of patients with LM was 12 months (95% CI 9– 17 months). On univariate analysis, NLR, PLR, SII, LMR, sex, smoking history, ECOG performance status (PS) scores, histological subtypes and targeted therapy were all significantly associated with OS. Only NLR (P=0.034, 95% CI 1.060– 4.578) and ECOG PS scores (P=0.019, 95% CI 0.137– 0.839) maintained a significant association with OS on multivariate analysis. Furthermore, patients with baseline NLR > 3.57 had significantly worse OS than patients with NLR ≤ 3.57 (median OS 7 vs 17 months), as did patients with ECOG PS scores > 2 vs ≤ 2 (median OS 4 vs 15 months). Conclusion: Both baseline NLR and PS scores at the time of LM diagnosis are helpful and available prognostic biomarkers for patients with LM from lung cancer.
- 1 March 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 179-187
Open AccessRole of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
Purpose: Several biomarkers, such as baseline neutrophil-to-lymphocyte ratio (NLR), have been more investigated in patients with brain metastases (BM), while their role in patients with leptomeningeal metastases (LM) has not been clarified. Considering the difference between the clinical behaviour of BM and LM, there is the need for addressing the role of these biomarkers in LM. Methods: The present study retrospectively analyzed 95 consecutive patients with LM from lung cancer who were diagnosed at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2016 and December 2019. Baseline NLR, platelet-to-lymphocyte ratio (PLR), systemic immunoinflammation index (SII), and lymphocyte‐to-monocyte ratio at diagnosis of LM were calculated based on complete blood count and correlated, along with other characteristics, with overall survival (OS) using univariate and multivariate analyses. The best cutoff values for systemic immunoinflammation biomarkers were derived using the surv_cutpoint function in R software, which optimized the significance of the split between Kaplan–Meier survival curves. Results: Median OS of patients with LM was 12 months (95% CI 9– 17 months). On univariate analysis, NLR, PLR, SII, LMR, sex, smoking history, ECOG performance status (PS) scores, histological subtypes and targeted therapy were all significantly associated with OS. Only NLR (P=0.034, 95% CI 1.060– 4.578) and ECOG PS scores (P=0.019, 95% CI 0.137– 0.839) maintained a significant association with OS on multivariate analysis. Furthermore, patients with baseline NLR > 3.57 had significantly worse OS than patients with NLR ≤ 3.57 (median OS 7 vs 17 months), as did patients with ECOG PS scores > 2 vs ≤ 2 (median OS 4 vs 15 months). Conclusion: Both baseline NLR and PS scores at the time of LM diagnosis are helpful and available prognostic biomarkers for patients with LM from lung cancer.
- Open Access
- 15 September 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (10)
Multidimensional modulation of systemic immune by neurosurgical tumor resection in patients with brain tumors
Objectives: Immune perturbation induced by tumor burden has been showed as the hallmark of brain tumors. To date, the vast majority of studies have focused heavily on local immune responses in the tumor microenvironment. Little is known about how the systemic immune macroenvironment is modulated by neurosurgical tumor resection in patients with brain tumors.Method: Medical records from patients with brain tumors admitted to the Department of Neurosurgery at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2021 and March 2022 were retrospectively reviewed. Forty‐nine patients who have lymphocyte subsets, serum immunoglobulins, C‐reactive protein, and complements levels before neurosurgical tumor resection and at least once test after surgery were included into the final analysis.Results: Postoperative CD3+ lymphocytes, CD4+ lymphocytes and CD4+ /CD8+ lymphocyte ratio presented bi‐phasic changes, which indicated an initial decrease and a subsequent increase after neurosurgical tumor resection. Moreover, neurosurgical tumor resection induced a decrease in natural killer lymphocytes and an increase in B lymphocytes that persisted through the entire observation period after surgery. Meanwhile, significant changes in humoral immunity characterized by a decrease in immunoglobulins (IgA, IgG, and IgM) levels and an increase in the CRP level occurred after neurosurgical tumor resection. In addition, patients with postoperative infection complication had a lower preoperative CD4+ /CD8+ lymphocyte ratio.Conclusions: These findings provide evidence that either cellular immunity or humoral immunity can be remodeled by neurosurgical tumor resection, and patients with disturbed systemic immunity have increased risk of infection after surgery.
- 15 September 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (10)
Open AccessMultidimensional modulation of systemic immune by neurosurgical tumor resection in patients with brain tumors
Objectives: Immune perturbation induced by tumor burden has been showed as the hallmark of brain tumors. To date, the vast majority of studies have focused heavily on local immune responses in the tumor microenvironment. Little is known about how the systemic immune macroenvironment is modulated by neurosurgical tumor resection in patients with brain tumors.Method: Medical records from patients with brain tumors admitted to the Department of Neurosurgery at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2021 and March 2022 were retrospectively reviewed. Forty‐nine patients who have lymphocyte subsets, serum immunoglobulins, C‐reactive protein, and complements levels before neurosurgical tumor resection and at least once test after surgery were included into the final analysis.Results: Postoperative CD3+ lymphocytes, CD4+ lymphocytes and CD4+ /CD8+ lymphocyte ratio presented bi‐phasic changes, which indicated an initial decrease and a subsequent increase after neurosurgical tumor resection. Moreover, neurosurgical tumor resection induced a decrease in natural killer lymphocytes and an increase in B lymphocytes that persisted through the entire observation period after surgery. Meanwhile, significant changes in humoral immunity characterized by a decrease in immunoglobulins (IgA, IgG, and IgM) levels and an increase in the CRP level occurred after neurosurgical tumor resection. In addition, patients with postoperative infection complication had a lower preoperative CD4+ /CD8+ lymphocyte ratio.Conclusions: These findings provide evidence that either cellular immunity or humoral immunity can be remodeled by neurosurgical tumor resection, and patients with disturbed systemic immunity have increased risk of infection after surgery.
- Open Access
- 7 September 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (10)
Systemic immune‐inflammation landscape in brain metastasis needing neurosurgical resection: Analysis of 230 consecutive cases in a single center
Background: Systemic immune‐inflammation states across the heterogeneous population of brain metastases are very important in the context of brain‐immune bidirectional communication, especially among the patients needing neurosurgical resection. Four blood cell ratios based on complete blood count (CBC) test serving as prognostic biomarkers have been highlighted by previous studies, including systemic immune‐inflammation index (SII), neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR). However, the presurgical systemic immune‐inflammation landscape in brain metastasis needing neurosurgical resection is limited.Methods: Patients with brain metastases admitted to the Department of Neurosurgery at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2016 and December 2019 were included. Based on peripheral blood cell counts in CBC test before neurosurgical resection, four systemic immune‐inflammation biomarkers (SII, NLR, PLR, and LMR) were calculated. We characterized the changes of SII, NLR, PLR, and LMR in patients with brain metastasis before neurosurgical resection and the associations of these types of immune‐inflammation states with patient demographics. In parallel, the corresponding data from the relative healthy populations without systemic diseases were enrolled as the control in the present study.Results: Brain metastases induced systemic immune‐inflammation perturbation, which was characterized by a significant increase in SII (p < .01) and NLR levels (p < .01) and a significant decrease in the LMR level (p < .01) in comparison with the healthy control group. Moreover, patients with male gender, less Karnofsky Performance Status (KPS) scores (<70), specific pathological subtypes, extracranial transfer, and history of both systemic and radiation therapy may have significant differences in one or more of these biomarkers, which indicated poorer systemic immune‐inflammation states.Conclusions: This study provides evidence that brain metastasis is associated with perturbations in presurgical systemic immune‐inflammation states. We should pay attention to the systemic immune‐inflammation perturbations following brain metastasis in clinic, especially in the subpopulations with high risks.
- 7 September 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (10)
Open AccessSystemic immune‐inflammation landscape in brain metastasis needing neurosurgical resection: Analysis of 230 consecutive cases in a single center
Background: Systemic immune‐inflammation states across the heterogeneous population of brain metastases are very important in the context of brain‐immune bidirectional communication, especially among the patients needing neurosurgical resection. Four blood cell ratios based on complete blood count (CBC) test serving as prognostic biomarkers have been highlighted by previous studies, including systemic immune‐inflammation index (SII), neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR). However, the presurgical systemic immune‐inflammation landscape in brain metastasis needing neurosurgical resection is limited.Methods: Patients with brain metastases admitted to the Department of Neurosurgery at the National Cancer Center, Cancer Hospital of Chinese Academy of Medical Sciences between January 2016 and December 2019 were included. Based on peripheral blood cell counts in CBC test before neurosurgical resection, four systemic immune‐inflammation biomarkers (SII, NLR, PLR, and LMR) were calculated. We characterized the changes of SII, NLR, PLR, and LMR in patients with brain metastasis before neurosurgical resection and the associations of these types of immune‐inflammation states with patient demographics. In parallel, the corresponding data from the relative healthy populations without systemic diseases were enrolled as the control in the present study.Results: Brain metastases induced systemic immune‐inflammation perturbation, which was characterized by a significant increase in SII (p < .01) and NLR levels (p < .01) and a significant decrease in the LMR level (p < .01) in comparison with the healthy control group. Moreover, patients with male gender, less Karnofsky Performance Status (KPS) scores (<70), specific pathological subtypes, extracranial transfer, and history of both systemic and radiation therapy may have significant differences in one or more of these biomarkers, which indicated poorer systemic immune‐inflammation states.Conclusions: This study provides evidence that brain metastasis is associated with perturbations in presurgical systemic immune‐inflammation states. We should pay attention to the systemic immune‐inflammation perturbations following brain metastasis in clinic, especially in the subpopulations with high risks.
- Open Access
- 10 January 2022
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 29, 101203
Identification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis
- 10 January 2022
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 29, 101203
Open AccessIdentification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Clinical Pictures and Paraneoplastic Antibody Repertoire of 17 Chinese Anti-GABAB Receptor Encephalitis Patients : A Retrospective Study (P6.130)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Clinical Pictures and Paraneoplastic Antibody Repertoire of 17 Chinese Anti-GABAB Receptor Encephalitis Patients : A Retrospective Study (P6.130)